DexCom 任命现任 CFO Jereme Sylvain 兼任首席运营官（COO），属内部职责扩张

----- dxcm-20260910.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
September 10, 2026
DEXCOM, INC.
(Exact Name of the Registrant as Specified in Its Charter)
Delaware
000-51222
33-0857544
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
6340 Sequence Drive
,
San Diego
,
CA
92121
(Address of Principal Executive Offices)
(
Zip Code)
(
858
)
200-0200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 Par Value Per Share
DXCM
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
In connection with Mr. Sylvain’s promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the “Offer Letter”) providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan, to participate in the Company’s Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.
Biographical and other information for Mr. Sylvain is set forth in Dexcom’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2026, and is incorporated herein by reference. There is no arrangement or understanding between Mr. Sylvain and any other persons pursuant to which such person was selected as an officer. There are no family relationships among any of Dexcom’s directors or executive officers and Mr. Sylvain, and Mr. Sylvain does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the Offer Letter, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
ITEM 7.01. REGULATION FD DISCLOSURE.
On September 14, 2026, Dexcom announced the promotion of Mr. Sylvain in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Number
Description
99.1
Press release dated September 14, 2026
104
Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DEXCOM, INC.
By:
/s/ JEREME SYLVAIN
Jereme Sylvain
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Date:
September 14, 2026

----- dxcm20260914-exhibit991.htm -----
EX-99.1
2
dxcm20260914-exhibit991.htm
EX-99.1
Document
Exhibit 99.1
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO - (BUSINESS WIRE- September 14, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcom’s global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence.
Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership team and guided the company’s journey of growth and margin expansion. He has also demonstrated the ability to align and execute cross-functionally, bringing the combination of strategic judgment, operational discipline, and commitment to customers that are key for Dexcom’s next phase of growth and scale.
“Jereme is an exceptional leader and a valued strategic partner across Dexcom,” said Jake Leach, President and CEO. “His deep understanding of our business, operational discipline and customer focus make him the right leader for this expanded role. I am confident that Jereme will help us scale more effectively as we advance our goal to empower millions more people to take control of health.”
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit Dexcom.com.
Category: IR
Media Contact
Nadia Conard
mediarelations@dexcom.com
Investor Contact
Sean Christensen
investor-relations@dexcom.com